Back to Search
Start Over
A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.
- Source :
- OncoTargets & Therapy; Dec2015, Vol. 8, p3561-3564, 4p, 2 Black and White Photographs
- Publication Year :
- 2015
-
Abstract
- The subset of metastatic colorectal adenocarcinomas that harbor BRAF V600E mutations are aggressive tumors with significantly shortened survival and limited treatment options. Here we present a colorectal cancer patient whose disease progressed through standard chemotherapy and who developed liver metastasis. Comprehensive genomic profiling (FoundationOne<superscript>®</superscript>) identified a BRAF V600E mutation in the liver lesion, as well as other genomic alterations consistent with colorectal cancers. Combination therapy of dabrafenib and trametinib with standard cytotoxic chemotherapy resulted in a durable major ongoing response for the patient. This report illustrates the utility of comprehensive genomic profiling with personalized targeted therapy for aggressive metastatic colorectal adenocarcinomas. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 11786930
- Volume :
- 8
- Database :
- Complementary Index
- Journal :
- OncoTargets & Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 112158037
- Full Text :
- https://doi.org/10.2147/OTT.S90766